Brief: Immuneering Announces Overall Survival of First-Line Pancreatic Cancer Patients Treated With Atebimetinib + mGnP
24/09/2025 23:21
Sept 24 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING ANNOUNCES EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP IMMUNEERING CORP - ATEBIMETINIB + MGNP SHOWS 53% PFS AT 9 MONTHS IN PANCREATIC CANCER IMMUNEERING CORP - EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 IMMUNEERING CORP - TO INITIATE PIVOTAL TRIAL BY END OF 2025 Source text: ID:nGNX6frVjR Further company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences